false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Refresher on Selecting Genetic Testing for Ovarian ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The webinar discussed the selection of genetic testing for ovarian cancer treatment decisions. It highlighted the importance of germline testing and tumor testing in patients with advanced stage ovarian cancer. The focus was on identifying BRCA1 and BRCA2 mutations, as well as other genetic mutations associated with ovarian cancer. The webinar discussed the use of HRD testing, which is a marker of homologous recombination deficiency, and its role in determining treatment options for patients. The webinar also presented the findings of several clinical trials, which showed the benefit of PARP inhibitors in the treatment of ovarian cancer. The use of PARP inhibitors as maintenance therapy for patients with BRCA mutations and HRD positive tumors was recommended. The webinar also discussed the importance of genetic counseling and the role of the genetic counselor in helping patients make informed decisions about genetic testing. Overall, the webinar highlighted the importance of genetic testing in guiding treatment decisions for patients with ovarian cancer.
Keywords
genetic testing
ovarian cancer
germline testing
tumor testing
BRCA1
BRCA2
HRD testing
PARP inhibitors
Contact
education@igcs.org
for assistance.
×